HRP20020088B1 - Levodopa/karbidopa/entakapon farmaceutski pripravak - Google Patents

Levodopa/karbidopa/entakapon farmaceutski pripravak

Info

Publication number
HRP20020088B1
HRP20020088B1 HR20020088A HRP20020088A HRP20020088B1 HR P20020088 B1 HRP20020088 B1 HR P20020088B1 HR 20020088 A HR20020088 A HR 20020088A HR P20020088 A HRP20020088 A HR P20020088A HR P20020088 B1 HRP20020088 B1 HR P20020088B1
Authority
HR
Croatia
Prior art keywords
levodopa
carbidopa
entacapone
entacapon
pharmaceutical preparation
Prior art date
Application number
HR20020088A
Other languages
English (en)
Croatian (hr)
Inventor
Kallioinen Sari
Kervinen Lasse
Laaksonen Marja
Lintulaakso Jarmo
Niskanen Mervi
Partanen Marja
Ritala Marja
Vahervuo Kari
Virkki Matti
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020088(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of HRP20020088A2 publication Critical patent/HRP20020088A2/xx
Publication of HRP20020088B1 publication Critical patent/HRP20020088B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HR20020088A 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski pripravak HRP20020088B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation

Publications (2)

Publication Number Publication Date
HRP20020088A2 HRP20020088A2 (en) 2005-10-31
HRP20020088B1 true HRP20020088B1 (hr) 2007-05-31

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020088A HRP20020088B1 (hr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski pripravak

Country Status (42)

Country Link
US (2) US6500867B1 (cs)
EP (1) EP1189608B1 (cs)
JP (2) JP4204783B2 (cs)
KR (1) KR100905428B1 (cs)
CN (1) CN1168440C (cs)
AR (1) AR033796A1 (cs)
AT (1) ATE245417T1 (cs)
AU (1) AU765932B2 (cs)
BG (1) BG65364B1 (cs)
BR (2) BRPI0011867B8 (cs)
CA (1) CA2378469C (cs)
CO (1) CO5180579A1 (cs)
CZ (2) CZ303010B6 (cs)
DE (1) DE60004052T2 (cs)
DK (1) DK1189608T3 (cs)
EA (1) EA004503B1 (cs)
EE (1) EE05473B1 (cs)
ES (1) ES2203495T3 (cs)
FI (1) FI109453B (cs)
FR (1) FR2797587A1 (cs)
GE (1) GEP20043314B (cs)
HK (1) HK1047040B (cs)
HR (1) HRP20020088B1 (cs)
HU (1) HU230395B1 (cs)
IL (1) IL146807A (cs)
IT (1) ITMI20001450A1 (cs)
ME (1) ME00520B (cs)
MX (1) MXPA01013167A (cs)
MY (1) MY127685A (cs)
NO (2) NO330260B1 (cs)
NZ (1) NZ515780A (cs)
PE (1) PE20010399A1 (cs)
PL (1) PL197818B1 (cs)
PT (1) PT1189608E (cs)
RS (1) RS50368B (cs)
SI (1) SI1189608T1 (cs)
SK (1) SK286451B6 (cs)
TR (1) TR200103763T2 (cs)
TW (1) TWI241187B (cs)
UA (1) UA75047C2 (cs)
WO (1) WO2001001984A1 (cs)
ZA (1) ZA200109868B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
JP2006506362A (ja) * 2002-10-11 2006-02-23 デポメド・ディベロップメント・リミテッド 胃内保持型レボドパデリバリー形態
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
EP2335696A1 (en) * 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
JP5517453B2 (ja) 2005-07-26 2014-06-11 ノヴィファーマ，エス．アー． Ｃｏｍｔ阻害剤
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
EP1948153A2 (en) * 2005-09-21 2008-07-30 Orion Corporation Treatment of symptoms of parkinson`s disease
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
EP1954256A2 (en) * 2005-11-09 2008-08-13 Torrent Pharmaceuticals Ltd Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US8741342B2 (en) * 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
BRPI0721213B1 (pt) 2007-01-31 2021-11-09 Bial - Portela & Ca, S.A. Uso de nitrocatecóis substituídos, e embalagem
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
WO2009098663A1 (en) * 2008-02-06 2009-08-13 Wockhardt Research Centre Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
MX2010008711A (es) * 2008-02-06 2011-05-03 Wockhardt Ltd Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
EP2276758B1 (en) 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
EP2328565B1 (en) * 2008-08-22 2014-06-04 Wockhardt Limited An extended release pharmaceutical composition of entacapone or salts thereof
WO2010020970A1 (en) 2008-08-22 2010-02-25 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20120027197A (ko) 2009-04-01 2012-03-21 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
SG10201709016RA (en) 2009-05-19 2017-11-29 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
WO2011075912A1 (zh) 2009-12-25 2011-06-30 台湾东洋药品工业股份有限公司 治疗帕金森氏症的医药组合物及其制备方法
MX336187B (es) * 2010-03-04 2016-01-07 Orion Corp Metodo para tratar el mal de parkinson.
DE102010023828A1 (de) 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
ES2776734T3 (es) * 2010-11-15 2020-07-31 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
MX2013012429A (es) * 2011-04-26 2013-12-06 Innopharmax Inc Una composicion de entacopone.
DK2791134T3 (da) 2011-12-13 2019-12-09 BIAL PORTELA & Cª S A Kemisk forbindelse, der er anvendelig som mellemprodukt til fremstilling af en catechol-o-methyltransferasehæmmer
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
CN110935026A (zh) * 2013-03-13 2020-03-31 纽罗德姆有限公司 帕金森病的治疗方法
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2015136538A1 (en) 2014-03-13 2015-09-17 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
PT3782617T (pt) 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
WO2016101969A1 (en) 2014-12-23 2016-06-30 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
CN109689036A (zh) * 2016-07-11 2019-04-26 康特拉医药公司 用于治疗早晨运动不能的脉冲药物输送系统
EA036784B1 (ru) 2016-08-18 2020-12-21 Илько Илач Санайи Ве Тиджарет Аноним Ширкети Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
KR20250043584A (ko) 2018-03-23 2025-03-28 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
TR200103763T2 (tr) 2002-04-22
CO5180579A1 (es) 2002-07-30
NO20016203L (no) 2002-02-25
HUP0202273A2 (en) 2002-10-28
JP4204783B2 (ja) 2009-01-07
EP1189608A1 (en) 2002-03-27
JP2003503454A (ja) 2003-01-28
PL352775A1 (en) 2003-09-08
CZ304416B6 (cs) 2014-04-23
CZ303010B6 (cs) 2012-02-29
AU5830600A (en) 2001-01-22
BG106251A (en) 2002-08-30
PT1189608E (pt) 2003-12-31
FR2797587A1 (fr) 2001-02-23
UA75047C2 (en) 2006-03-15
NO20016203D0 (no) 2001-12-18
PL197818B1 (pl) 2008-04-30
BRPI0011867B1 (pt) 2019-01-08
CZ20014636A3 (cs) 2002-05-15
US20030017201A1 (en) 2003-01-23
HRP20020088A2 (en) 2005-10-31
HUP0202273A3 (en) 2002-11-28
AR033796A1 (es) 2004-01-07
PE20010399A1 (es) 2001-04-10
US6797732B2 (en) 2004-09-28
CN1168440C (zh) 2004-09-29
HK1047040A1 (en) 2003-02-07
FI109453B (fi) 2002-08-15
YU92501A (sh) 2004-09-03
KR20020010155A (ko) 2002-02-02
NO330260B1 (no) 2011-03-14
CA2378469C (en) 2009-10-06
BR0011867A (pt) 2002-03-05
WO2001001984A1 (en) 2001-01-11
MY127685A (en) 2006-12-29
DK1189608T3 (da) 2003-11-10
CA2378469A1 (en) 2001-01-11
EA004503B1 (ru) 2004-04-29
HU230395B1 (hu) 2016-04-28
DE60004052D1 (de) 2003-08-28
US6500867B1 (en) 2002-12-31
SK286451B6 (sk) 2008-10-07
MXPA01013167A (es) 2002-07-02
FI991485L (fi) 2000-12-31
TWI241187B (en) 2005-10-11
JP4885896B2 (ja) 2012-02-29
ZA200109868B (en) 2003-05-28
ITMI20001450A1 (it) 2001-12-28
SK19232001A3 (sk) 2002-06-04
BG65364B1 (bg) 2008-04-30
NO20110090L (no) 2002-02-25
DE60004052T2 (de) 2004-04-15
ITMI20001450A0 (it) 2000-06-28
EE05473B1 (et) 2011-10-17
RS50368B (sr) 2009-11-10
CN1358090A (zh) 2002-07-10
EA200200106A1 (ru) 2002-06-27
ME00520B (me) 2011-10-10
NZ515780A (en) 2004-06-25
SI1189608T1 (en) 2004-04-30
HK1047040B (zh) 2005-04-29
AU765932B2 (en) 2003-10-02
BRPI0011867B8 (pt) 2021-05-25
EP1189608B1 (en) 2003-07-23
ES2203495T3 (es) 2004-04-16
FI991485A0 (fi) 1999-06-30
JP2008156373A (ja) 2008-07-10
IL146807A (en) 2006-10-05
GEP20043314B (en) 2004-02-10
EE200100716A (et) 2003-02-17
KR100905428B1 (ko) 2009-06-30
ATE245417T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
HRP20020088B1 (hr) Levodopa/karbidopa/entakapon farmaceutski pripravak
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
GEP20022784B (en) Celecoxib Composition
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
ATE252892T1 (de) Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
NZ503946A (en) Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
TR200000369T2 (tr) Romatizmal hastalıkların tedavisinde kullanılmak üzere kombine farmasötik preparatların üretilmesi.
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AP2003002763A0 (en) Controlled release formulations for oral administration
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
JP2002540148A5 (cs)
BR0014440A (pt) Formulações de liberação controlada oral
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
BE2016C017I2 (cs)
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
IT1293835B1 (it) Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190614

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200629